Skip to main content

PTC Therapeutics, Inc.

PTCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001070081

In the last 90 days, PTC Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 384 institutions reported holding it in 13F filings for Q2 2026, worth $8.20B in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 30, 2026, 1:16 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of PTC Therapeutics, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026Jan 13, 2025Jan 8, 2024Jan 9, 2023Jan 10, 2022
Revenue$1.73B$806.8M$937.8M$698.8M$538.6M
Operating expenses$863.7M$1.11B$1.38B$1.15B$913.0M
Research and development$455.2M$534.5M$666.6M$651.5M$540.7M
Selling, general and administrative$347.1M$300.9M$332.5M$326.0M$285.8M
Operating income$866.9M-$302.6M-$439.5M-$447.4M-$374.4M
Income tax$14.0M$176.0K-$69.5M-$28.5M$5.56M
Net income$682.6M-$363.3M-$626.6M-$559.0M-$523.9M
EPS, basic$8.58$-4.73$-8.37$-7.79$-7.43
EPS, diluted$7.78$-4.73$-8.37$-7.79$-7.43
Weighted shares, basic79.5M76.8M74.8M71.7M70.5M
Weighted shares, diluted88.3M76.8M74.8M71.7M70.5M
Margins and growth
Operating margin50.1%-37.5%-46.9%-64.0%-69.5%
Net margin39.4%-45.0%-66.8%-80.0%-97.3%
Revenue growth, year over year+114.5%−14.0%+34.2%+29.7%+41.4%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of PTC Therapeutics, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026Jan 13, 2025Jan 8, 2024Jan 9, 2023Jan 10, 2022
Cash and equivalents$984.6M$779.7M$594.0M$279.8M$189.7M
Short-term investments$960.7M$360.0M$282.7M$130.9M$583.7M
Accounts receivable$181.6M$158.6M$160.8M$155.6M$110.5M
Inventory$79.6M$23.2M$30.6M$21.8M$15.9M
Total current assets$2.27B$1.37B$1.22B$693.8M$954.4M
Property, plant and equipment$55.4M$61.0M$87.1M$72.6M$52.6M
Goodwill$82.3M$82.3M$82.3M$82.3M$82.3M
Intangible assets$388.8M$118.8M$379.5M$705.9M$724.8M
Total assets$2.90B$1.71B$1.90B$1.71B$1.94B
Accounts payable$45.5M$17.3M$6.04M$27.3M$23.0M
Short-term debt$286.6M–––$149.5M
Total current liabilities$968.4M$581.0M$603.1M$406.2M$509.3M
Long-term debt–$285.4M$284.2M$571.7M$281.9M
Total liabilities$3.10B$2.80B$2.71B$2.05B$1.94B
Shareholders' equity-$205.3M-$1.10B-$818.6M-$347.1M$1.44M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of PTC Therapeutics, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026Jan 13, 2025Jan 8, 2024Jan 9, 2023Jan 10, 2022
Operating cash flow$711.2M-$107.7M-$158.4M-$356.7M-$251.3M
Capital expenditures$8.86M$6.50M$28.4M$32.0M$28.2M
Free cash flow$702.3M-$114.2M-$186.9M-$388.7M-$279.5M
Depreciation and amortization$38.8M$75.7M$236.6M$128.8M$64.1M
Stock-based compensation$74.5M$74.6M$101.6M$110.3M$103.5M
Investing cash flow-$862.0M$44.2M-$176.7M$290.2M$219.2M
Financing cash flow$331.1M$255.9M$646.4M$168.0M$20.9M
Net change in cash$203.0M$185.0M$314.4M$98.7M-$19.1M
Ratio
Stock-based compensation, % of revenue4.3%9.2%10.8%15.8%19.2%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for PTC Therapeutics, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 27, 202683.5M+4.1%SEC
Jul 29, 202683.5M+5.1%SEC
May 5, 20268.29M−89.5%SEC
Feb 18, 202682.8M+5.0%SEC
Nov 3, 202580.3M+4.1%SEC
Aug 5, 202579.4M+3.3%SEC
May 4, 202579.3M+3.3%SEC
Feb 25, 202578.9M+3.0%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.